Therapeutic repurposing of Pioglitazone for slowing the progression of Mild-Moderate Alzheimer’s Disease: A systematic review and meta-analysis

Pioglitazone is an emerging therapy in treating Alzheimer disease (AD), but there is lack of evidence supporting its efficacy. The objectives of this study were to determine the safety and efficacy of Pioglitazone in slowing the progression of Alzheimer disease in patients with mildmoderate cognitive impairment. This review included Randomized Controlled Trials presenting the comparison between Pioglitazone and a suitable control. An extensive literature search was conducted and eligibility was checked based on the criteria prepared by the researchers. Five studies were included for outcome analysis. The scores of Alzheimer’s Disease Assessment Scale- Cognitive subscale (ADAS- Cog) [MD: -2.75; 95% CI: -4.84 to -0.66] showed a statistically significant improvement in cognition. The results of our study prove that Pioglitazone is a potential treatment for AD.

Author(s): Pooja Sudarsan, Roopa Satyanarayan Basutkar, Sandra Mariam Robin, Vahini B and Sivasankaran P

Warning: Undefined variable $art_rows in /efsdata/imedpub-com/abstract/abstract-page.php on line 110

Warning: Attempt to read property "select_abs_row" on null in /efsdata/imedpub-com/abstract/abstract-page.php on line 110

Abstract | PDF

Share This Article